In addition, Buddlejasaponin IV (BS-IV) acts as an anti-metastatic agent by reducing FAK and Akt phosphorylation levels, which inhibits the lung metastases of colon cancer cells [137]. This evidence concerns the gene AKT1 and malignant colon neoplasm.